Artikel
Overall survival of primary high-grade gliomas of supra- and infratentorial midline structures
Suche in Medline nach
Autoren
Veröffentlicht: | 8. Juni 2016 |
---|
Gliederung
Text
Objective: In the literature recent and roubust data on the prognosis of patients with high grade gliomas (HGG) WHO III° and IV° stratified by resectability, molecular features and different treatment modalities are available. However, little is known about the outcome of patients with HGG's located in supra- and infratentorial midline structures like the corpus callosum, basal ganglia and brainstem. In this study we evaluate overall survival (OS) and influencing factors of patients with de novo HGG specifically in those structures.
Method: In a single center retrospective analysis, we screened our database for all adult patients with primary HGG in midline structures diagnosed by stereotactic biopsy (SB) between January 1996 and March 2015. We evaluated OS and analyzed factors (MGMT status, treatment after SB, age, gender, Karnofsky Score (KPS), localization) influencing OS using Whitney-Mann-U and Chi-square test as well as cox regression analysis.
Results: 122 patients with HGG, who had undergonestereotactic biopsy procedures (median age: 56.3 (22-82) years; median KPS: 80 (50-100)%. Histology revealed glioma WHO III° in 31.1% and WHO IV° in 68.9%. Lesions were localized in the corpus callosum (50.0%), basal ganglia (18.9%), thalamus (9.0%), pineal region (2.5%), sella (0.8%), brainstem (18.9%). Median overall survival (mOS) was 6.3 months (95% CI, 3.6-9.0%), for WHO III°: 13.6 months (95% CI 5.6-21.6) and for WHO IV°: 4.9 months (95 % CI, 3.2-6.6). Patients were treated as follows: no specific tumor therapy (13.1%, 2 WHO III° and 15 WHO IV°; mOS 1.1 months) or various tumor specific therapy regimens (WHO III° 34 (32.4%) patients mOS 15.5 month [95% CI 7.4-23.6]), (WHO IV° 65 (61.9%) patients mOS 10.6 months). In 6 patients (5.7%) the type of adjuvant therapy is unknown. MGMT promotor methylation status was available for 46 treated tumor patients (18 WHO III°, 28 WHO IV°). mOS of patients with WHO IV tumors was significantly worse than WHO III° (p<0.0001). Any tumor specific treatment improved survival significantly (p=0.005). Poor clinical condition (KPS<70) and no tumor specific therapy were the significant factors for poor OS in multivariate analysis (adjusted HR 1.88 CI95% 1.03-3.92 p=0.04 and 11.09 CI95% 5.24-23.35 p<0.0001 respectively).
Conclusions: Overall survival of de novo HGG's, especially of WHO IV tumors located in midline structures is poor. Specific tumor treatment improves survival significantly. Treatment decision should be based on the patient's clinical status for the best quality of life.